研究和试验发展

Search documents
白云山成立分子科技公司
Mei Ri Jing Ji Xin Wen· 2025-10-09 01:14
每经AI快讯,天眼查工商信息显示,近日,广药云山分子科技(广州)有限公司成立,法定代表人为孔箭,注册资本5亿元人民币,经营范围为医学研究和 试验发展,技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广,以自有资金从事投资活动,第二类医疗器械销售,食品互联网销售,食品销 售。股东信息显示,该公司由白云山(600332)全资持股。 | | | 皇公司 都在用的商业查询工具 | 查关系 查风险 省老板 | | | | --- | --- | --- | --- | --- | --- | | | | 国家中小企业发展子基金旗下机构 | 广药云山分子科技(广州)有限公司 | × 天眼一下 | | | 基本信息 17 | | 法律诉讼 | 经营风险 | 经营信息 | 公 | | 法定代表人 | | 孔箭 猛关联企业 4 FL | 登记状态 ② | 存续 | | | | | | 成立日期 | 2025-09-30 | | | 统一社会信用代码 2 | | 91440112MAEWX6L36M | 注册资本 2 | 50000万人民币 | | | 工商注册号 | | 440112005294751 | 纳税人识别号 ...
嫦娥六号月球背面样品研究取得新成果
Xin Hua Cai Jing· 2025-10-06 01:28
中秋佳节来临之际,我国月壤研究再传喜报。国家航天局和国家原子能机构6日联合发布嫦娥六号月球背面样品研究最新成果——我国科学家首次基于嫦娥 六号月球背面样品(月壤)研究发现,月球背面月幔比月球正面月幔温度低,这一发现为月球演化和"二分性"特征研究提供了关键科学数据。 这项研究成果由中核集团核工业北京地质研究院(以下简称"核地研院")、北京大学、山东大学共同合作完成,已刊发于国际学术期刊《自然·地球科学》 (Nature Geoscience)官网。 在研究中,科学家利用可"侦探"的多种手段,对我国嫦娥六号从月球背面带回的玄武岩样品进行了精细分析。这些样本的化学成分如同一个"黑匣子",记录 了其形成时的深部温度压力等信息。 科研团队通过对月壤玄武岩样品中典型单斜辉石、斜长石等矿物的成分分析,运用"单斜辉石单矿物温压计""单斜辉石-熔体平衡温压计""斜长石-熔体平衡温 度计"三种不同的温压计来计算单斜辉石、斜长石结晶温度与压力。为确保研究结果的科学性,团队通过岩石学模型模拟了嫦娥六号玄武岩结晶过程。以上 四种独立方法得出了一致结果:嫦娥六号玄武岩样品的结晶温度约为1100摄氏度,比来自月球正面的嫦娥五号等样品低约1 ...
1.61亿元!中国科学院物理研究所采购大批仪器设备
仪器信息网· 2025-09-28 03:57
摘要 : 近日,中国科学院物理研究所发布多批政府采购意向,仪器信息网特对其中的仪器设备品目进行梳理,统计出59项仪器设备 采购意向,预算总额达1.61亿元。 特别提示 微信机制调整,点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标,否则很可能无法看到我们的推送。 近日, 中国科学院物理研究所发布 59 项仪器设备采购意向,预算总额达 1.61 亿 元,涉及物性测量系统 、拉曼光 谱仪、测量分析系统、激光器 、抛光系统 等,预计采购时间为 202 5 年 7 ~ 9 月 。 详细采购清单: 中国科学院物理研究所 202 5 年 7~9 月 仪器设备采购 意向汇总表 ↓ ↓ ↓ | 转 载 : 须 本 号 授 权 , 请 联 系 主 编 | 采购 | 需求 | 预算 | 采购 | | --- | --- | --- | --- | | 项目 | 概况 | 万元 | 时间 | | 物性测量系统 | 达到实验需求。 580 | | 202 5 年 7 月 | | 拉曼光谱仪 | | 255 | 202 5 年 7 月 | | 激光器 | | 230 | 202 5 年 7 月 | | 制冷机 | | 98 ...
皓元医药:9月26日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-26 08:39
截至发稿,皓元医药市值为168亿元。 每经头条(nbdtoutiao)——5年增长33倍,这类新险种卖爆了,身边很多人都需要,30多家险企蜂拥而 入⋯⋯ (记者 曾健辉) 每经AI快讯,皓元医药(SH 688131,收盘价:79.22元)9月26日晚间发布公告称,公司第四届第十二 次董事会会议于2025年9月26日在上海市浦东新区张衡路1999弄3号楼公司会议室以现场结合通讯方式召 开。会议审议了《关于调整2023年、2025年限制性股票激励计划授予价格的议案》等文件。 2024年1至12月份,皓元医药的营业收入构成为:研究和试验发展行业占比99.27%,其他业务占比 0.73%。 ...
预算1.75亿元!中国科学院高能物理研究所近期大批仪器采购意向
仪器信息网· 2025-09-22 08:58
Core Viewpoint - The Chinese Academy of Sciences High Energy Physics Institute has announced a procurement intention for 20 items of scientific instruments and equipment, with a total budget of 175 million yuan, expected to be purchased between April and November 2025 [2][3]. Procurement Overview - The procurement includes high-gradient superconducting cavity systems, low-temperature temperature sensors, high-efficiency energy recovery type klystrons, photodetector arrays, and inductively coupled plasma mass spectrometers [3][5]. - The total budget for these items is 175 million yuan, indicating significant investment in advanced scientific research equipment [3][5]. Detailed Procurement List - High-gradient superconducting cavity system: Budget of 12.5 million yuan, aimed at developing key system equipment for particle acceleration [5]. - Low-temperature temperature sensor: Budget of 3.1 million yuan, designed for high precision temperature measurement in strong magnetic and radiation environments [5]. - High-efficiency energy recovery klystron: Budget of 2.5 million yuan, with a continuous wave output power of 800 kW and efficiency over 85% [5]. - Photodetector array: Budget of 1.95 million yuan, intended for maintenance and performance upgrades of the SiPM camera core device [5]. - Inductively coupled plasma mass spectrometer: Budget of 1.9 million yuan, for quality control of isotopes produced in research [5]. Additional Equipment and Upgrades - The procurement also includes various upgrades and new installations for existing equipment, such as temperature measurement devices and control systems for power cabinets [6][7]. - Specific items include 3He tube neutron detectors for cold non-elastic spectrometers and backscattering spectrometers, with budgets of 8.736 million yuan and 8.2 million yuan respectively [7]. Conclusion - The procurement plan reflects a strategic investment in high-tech scientific instruments, which is expected to enhance research capabilities in high-energy physics and related fields [2][3].
下周审核4家IPO,2家再融资。其中两家IPO企业于在审期间调减募资规模
Sou Hu Cai Jing· 2025-09-21 20:17
IPO and Financing Overview - Four companies are scheduled for IPO review next week (September 22-26), with a total fundraising target of 12.233 billion yuan [1] - The companies include Bai'ao Saitu, Wei Dongguang, Mo'er Thread, and Nanfang Digital, each from different sectors such as biotechnology and software services [1][8] Company Summaries Bai'ao Saitu - Bai'ao Saitu plans to raise 1.185 billion yuan, down from an initial target of 1.893 billion yuan [2] - The company specializes in preclinical CRO and biotechnology services, focusing on gene editing technology and drug discovery [9] - Recent financial performance shows a net profit of 33.54 million yuan for the last year, with total assets of 2.415 billion yuan [11] Wei Dongguang - Wei Dongguang aims to raise 494 million yuan, reduced from an initial 651 million yuan [5] - The company operates in the computer and communication equipment manufacturing sector, focusing on passive optical devices [13] - The latest financial data indicates a net profit of 12.36 million yuan for the previous year [26] Mo'er Thread - Mo'er Thread is targeting a fundraising of 800 million yuan, with a focus on GPU and related products [18] - The company has developed a range of GPU architectures and aims to expand into AI and cloud computing applications [18] - Financial results show a net loss of 149.19 million yuan for the last year, with total assets of 702.16 million yuan [19] Nanfang Digital - Nanfang Digital plans to raise 2.554 billion yuan, focusing on digital solutions for the power and energy sectors [21] - The company is controlled by the State-owned Assets Supervision and Administration Commission, indicating strong governmental backing [21] - Recent financial performance shows a net profit of 1.547 million yuan for the first half of 2025 [23] Fundraising Projects - Bai'ao Saitu's fundraising will be allocated to projects such as early drug research and development services, with a total investment of 5.938 billion yuan [4][12] - Wei Dongguang's funds will support the expansion of its manufacturing base and working capital [6][7] - Mo'er Thread's fundraising will focus on AI chip development and related projects, with a total investment of 800 million yuan [20] - Nanfang Digital's funds will be used for various digital infrastructure projects aimed at enhancing energy sector efficiency [25]
海通证券保荐益诺思IPO项目质量评级B级 实际募集金额缩水近6成 上市首年增收不增利
Xin Lang Zheng Quan· 2025-09-19 08:12
Company Overview - Full Name: Shanghai Yinuosi Biotechnology Co., Ltd [1] - Abbreviation: Yinuosi [1] - Stock Code: 688710.SH [1] - IPO Application Date: December 29, 2022 [1] - Listing Date: September 3, 2024 [1] - Listing Board: Shanghai Stock Exchange Sci-Tech Innovation Board [1] - Industry: Research and Experimental Development [1] - IPO Sponsor: Haitong Securities [1] - Lead Underwriters: Haitong Securities [1] - Legal Advisor: Guohao Law Firm (Shanghai) [1] - Audit Firm: Lixin Certified Public Accountants (Special General Partnership) [1] Disclosure and Evaluation - Disclosure Issues: The actual controller, China National Pharmaceutical Group, has inconsistencies in the main business of its subsidiary related to the issuer, requiring clarification on the completeness of similar business entities [1] - Regulatory Penalties: No penalties [2] - Public Supervision: No penalties [2] - Listing Cycle: Yinuosi's listing cycle is 614 days, shorter than the average of 629.45 days for A-share companies in 2024 [2] - Multiple Applications: Yinuosi is not categorized as having multiple applications [2] Financial Metrics - Issuance Costs: The underwriting and sponsorship fees amount to 44.4235 million yuan, with a commission rate of 6.61%, lower than the average of 7.71% [3] - First Day Performance: The stock price increased by 41.61% on the first day of listing [3] - Three-Month Performance: The stock price rose by 108.39% within three months of listing [4] - Issuance Price-Earnings Ratio: The issuance P/E ratio is 15.40 times, which is 83.83% of the industry average of 18.37 times [5] - Actual Fundraising: Expected fundraising is 1.664 billion yuan, but actual fundraising is only 672 million yuan, a decrease of 59.63% [6] Short-term Performance - Revenue Growth: In 2024, the company's revenue increased by 9.94% year-on-year [7] - Net Profit Decline: The net profit attributable to the parent company decreased by 24.00% year-on-year, and the non-recurring net profit dropped by 28.12% year-on-year [7] - Abandonment Rate: The abandonment rate is 0.23% [7] Overall Score - Total Score: Yinuosi's IPO project received a total score of 86, classified as B-level [7] - Negative Factors: The score is impacted by the need for improved disclosure quality, significant reduction in actual fundraising, decline in net profit in the first accounting year, and the abandonment rate of 0.23% [7]
百普赛斯:9月16日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-16 12:08
Group 1 - The company Baipusais (SZ 301080) announced the convening of its 20th meeting of the second board of directors on September 16, 2025, in Beijing, where it reviewed the proposal for the re-election of members of the strategic committee [1] - For the fiscal year 2024, Baipusais reported that 98.13% of its revenue came from research and experimental development, while other businesses accounted for 1.87% [1] - As of the report date, Baipusais has a market capitalization of 10.3 billion yuan [1]
毕得医药:七名股东计划减持不超过1%公司股份
Mei Ri Jing Ji Xin Wen· 2025-09-12 11:05
Group 1 - The core point of the news is that shareholders of Bid Pharma plan to reduce their holdings due to personal liquidity needs, with a total reduction not exceeding 1% of the company's total share capital [1] - Specific reduction details include: Li Yijing plans to reduce up to approximately 227,900 shares (0.25% of total share capital), Chen Jun up to approximately 136,400 shares (0.15%), Li Li up to approximately 136,400 shares (0.15%), Du Juan up to approximately 136,400 shares (0.15%), Li Aifei up to approximately 131,800 shares (0.15%), Geng Yong up to approximately 91,300 shares (0.1%), and Jiang Yamei up to approximately 48,000 shares (0.05%) [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1] Group 2 - For the year 2024, Bid Pharma's revenue composition is entirely from the research and experimental development industry, accounting for 100% [2] - As of the latest report, Bid Pharma has a market capitalization of 6.4 billion yuan [3]
毕得医药:股东舟山欣曦、宁波兰旦及其一致行动人吴波拟合计减持不超过公司总股本的2.86%股份
Mei Ri Jing Ji Xin Wen· 2025-09-05 11:29
Group 1 - Bid Pharma announced a shareholder reduction plan due to liquidity needs, with shareholders Zhoushan Xinxie, Ningbo Landan, and Mr. Wu Bo planning to reduce their holdings within three months after the announcement [1] - Zhoushan Xinxie and Ningbo Landan plan to reduce up to approximately 908,800 shares each, representing no more than 1% of the total share capital, while Mr. Wu Bo plans to reduce up to approximately 785,800 shares, representing no more than 0.86% of the total share capital [1] - The reduction price will be determined based on the market price at the time of the reduction [1] Group 2 - As of the report, Bid Pharma's market capitalization is 5.9 billion [2]